Annual report
9987.TEDINET S100R3L5
Period2022-04-01 → 2023-03-31
Filed2023-06-27
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.31T | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥2.24T | 2021-04-01 → 2022-03-31 | Cons. | Net sales |
| Revenue | ¥2.13T | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.21T | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.13T | 2018-04-01 → 2019-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥32.6bn | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Operating income | ¥20.1bn | 2021-04-01 → 2022-03-31 | Cons. | Operating income |
| Ordinary income | ¥36.4bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥23.4bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥18.3bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥41.5bn | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥36.2bn | 2018-04-01 → 2019-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥30.6bn | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥22.5bn | 2021-04-01 → 2022-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥20.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥14.4bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥7.9bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥28.2bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥30.2bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥20.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Net income | ¥14.5bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss |
| Total assets | ¥1.15T | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥1.14T | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥1.11T | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥1.11T | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥1.19T | at 2019-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥734.6bn | at 2023-03-31 | Cons. | Liabilities |
| Total liabilities | ¥723.7bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥411.5bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥418.1bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥417.9bn | at 2021-03-31d | Cons. | Net assets |
| Net assets / equity | ¥412.7bn | at 2020-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥401.6bn | at 2019-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥109.0bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥141.4bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥132.9bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥168.2bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥168.8bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥175.2bn | at 2020-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥217.0bn | at 2019-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥37.3bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥9.5bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥15.6bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥25.8bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥41.8bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥46.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥1.4bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥14.6bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥1.2bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥1.9bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥26.2bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥11.6bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥7.4bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥17.2bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥27.3bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥236.47 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥163.19 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥88.52 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥310.26 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥322.73 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥4,970.38 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,749.59 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,675.23 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,618.33 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,390.98 | at 2019-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 35.9% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.6% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 37.4% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 37.0% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.7% | at 2019-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 4.9% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 3.4% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 1.9% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 6.9% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.5% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 13,429 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 14,032 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 15,041 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 15,477 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 15,585 | at 2019-03-31d | Cons. | Number of employees |
| Revenue | ¥2.12T | 2022-04-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥2.04T | 2021-04-01 → 2022-03-31 | Standalone | Net sales |
| Revenue | ¥1.93T | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥2.00T | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥1.92T | 2018-04-01 → 2019-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥20.3bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Operating income | ¥10.4bn | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Ordinary income | ¥24.7bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥14.9bn | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥11.8bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥30.7bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥24.5bn | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥20.8bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥18.6bn | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Net income | ¥14.9bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥13.8bn | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | ¥6.0bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥21.7bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥24.7bn | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥1.05T | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥1.03T | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥1.00T | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.00T | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.08T | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥758.9bn | at 2023-03-31 | Standalone | Liabilities |
| Total liabilities | ¥723.8bn | at 2022-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥290.8bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥302.5bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥303.2bn | at 2021-03-31d | Standalone | Net assets |
| Net assets / equity | ¥301.0bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥296.1bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥63.5bn | at 2023-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥85.6bn | at 2022-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥172.97 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥156.55 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥67.15 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥238.38 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥263.43 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥72 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥72 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥72 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥72 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥69 | 2018-04-01 → 2019-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥3,515 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,440.25 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,398.64 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,375.27 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,244.37 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 27.7% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 29.5% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 30.2% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 30.0% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 27.4% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 5.0% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.6% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.0% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.3% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 8.2% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 82,831,000 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 103,344,000 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 103,344,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 103,344,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 103,344,000 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 3,232 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 3,430 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 4,116 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 4,244 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 4,401 | at 2019-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 75
| Segment | Item | Period | Value |
|---|---|---|---|
| The Healthcare Related Services Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥1.1bn |
| The Healthcare Related Services Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥658m |
| The Healthcare Related Services Businessreportable segment | employees | at 2023-03-31 | 1586 pure |
| The Healthcare Related Services Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥228.7bn |
| The Healthcare Related Services Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥39.4bn |
| The Healthcare Related Services Businessreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥189.3bn |
| The Healthcare Related Services Businessreportable segment | segment assets | at 2023-03-31 | ¥78.4bn |
| The Healthcare Related Services Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥2.0bn |
| The Insurance Pharmacy Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥589m |
| The Insurance Pharmacy Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥667m |
| The Insurance Pharmacy Businessreportable segment | employees | at 2023-03-31 | 2876 pure |
| The Insurance Pharmacy Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥87.7bn |
| The Insurance Pharmacy Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥87.7bn |
| The Insurance Pharmacy Businessreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥23m |
| The Insurance Pharmacy Businessreportable segment | segment assets | at 2023-03-31 | ¥37.6bn |
| The Insurance Pharmacy Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥2.0bn |
| The Pharmaceutical Distribution Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥15.6bn |
| The Pharmaceutical Distribution Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥6.7bn |
| The Pharmaceutical Distribution Businessreportable segment | employees | at 2023-03-31 | 8143 pure |
| The Pharmaceutical Distribution Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥2.23T |
| The Pharmaceutical Distribution Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥2.18T |
| The Pharmaceutical Distribution Businessreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥49.9bn |
| The Pharmaceutical Distribution Businessreportable segment | segment assets | at 2023-03-31 | ¥972.0bn |
| The Pharmaceutical Distribution Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥27.1bn |
| The Pharmaceutical Manufacturing Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥429m |
| The Pharmaceutical Manufacturing Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥615m |
| The Pharmaceutical Manufacturing Businessreportable segment | employees | at 2023-03-31 | 824 pure |
| The Pharmaceutical Manufacturing Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥44.4bn |
| The Pharmaceutical Manufacturing Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥10.6bn |
| The Pharmaceutical Manufacturing Businessreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥33.7bn |
| The Pharmaceutical Manufacturing Businessreportable segment | segment assets | at 2023-03-31 | ¥60.5bn |
| The Pharmaceutical Manufacturing Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥1.2bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2022-04-01 → 2023-03-31 | ¥17.7bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2022-04-01 → 2023-03-31 | ¥8.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2023-03-31 | ¥2.59T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2023-03-31 | ¥2.31T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥272.9bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2023-03-31 | ¥1.15T |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2023-03-31 | ¥32.3bn |
| The Healthcare Related Services Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥570m |
| The Healthcare Related Services Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥633m |
| The Healthcare Related Services Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥181.8bn |
| The Healthcare Related Services Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥39.0bn |
| The Healthcare Related Services Businessreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥142.8bn |
| The Healthcare Related Services Businessreportable segment | segment assets | at 2022-03-31 | ¥63.7bn |
| The Healthcare Related Services Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥2.2bn |
| The Insurance Pharmacy Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥703m |
| The Insurance Pharmacy Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥747m |
| The Insurance Pharmacy Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥88.8bn |
| The Insurance Pharmacy Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥88.8bn |
| The Insurance Pharmacy Businessreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥34m |
| The Insurance Pharmacy Businessreportable segment | segment assets | at 2022-03-31 | ¥38.9bn |
| The Insurance Pharmacy Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥2.3bn |
| The Pharmaceutical Distribution Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥13.1bn |
| The Pharmaceutical Distribution Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥7.3bn |
| The Pharmaceutical Distribution Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥2.15T |
| The Pharmaceutical Distribution Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥2.10T |
| The Pharmaceutical Distribution Businessreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥51.6bn |
| The Pharmaceutical Distribution Businessreportable segment | segment assets | at 2022-03-31 | ¥980.9bn |
| The Pharmaceutical Distribution Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥14.7bn |
| The Pharmaceutical Manufacturing Businessreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥549m |
| The Pharmaceutical Manufacturing Businessreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥913m |
| The Pharmaceutical Manufacturing Businessreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥43.9bn |
| The Pharmaceutical Manufacturing Businessreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥12.2bn |
| The Pharmaceutical Manufacturing Businessreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥31.7bn |
| The Pharmaceutical Manufacturing Businessreportable segment | segment assets | at 2022-03-31 | ¥59.0bn |
| The Pharmaceutical Manufacturing Businessreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥780m |
| Total Of Reportable Segments And Otherssegment total | capex | 2021-04-01 → 2022-03-31 | ¥14.9bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2021-04-01 → 2022-03-31 | ¥9.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2022-03-31 | ¥2.47T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2022-03-31 | ¥2.24T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥226.1bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2022-03-31 | ¥1.14T |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2022-03-31 | ¥20.0bn |
| The Pharmaceutical Distribution Businessreportable segment | employees | at 2023-03-31 | 3232 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,996
| Item | Context | Value | Unit |
|---|---|---|---|
| Gross profit | CurrentYearDuration | 179694000000 | JPY |
| Selling general and administrative expenses | Prior1YearDuration | 147216000000 | JPY |
| Selling general and administrative expenses | CurrentYearDuration | 147089000000 | JPY |
| Operating income | Prior1YearDuration | 20116000000 | JPY |
| Operating income | CurrentYearDuration | 32605000000 | JPY |
| Interest income noi | Prior1YearDuration | 196000000 | JPY |
| Interest income noi | CurrentYearDuration | 171000000 | JPY |
| Dividends income noi | Prior1YearDuration | 1571000000 | JPY |
| Dividends income noi | CurrentYearDuration | 1400000000 | JPY |
| Equity in earnings of affiliates noi | Prior1YearDuration | 694000000 | JPY |
| Equity in earnings of affiliates noi | CurrentYearDuration | 1175000000 | JPY |
| Real estate rent noi | Prior1YearDuration | 287000000 | JPY |
| Real estate rent noi | CurrentYearDuration | 397000000 | JPY |
| Subsidy income noi | Prior1YearDuration | 227000000 | JPY |
| Subsidy income noi | CurrentYearDuration | 485000000 | JPY |
| Other noi | Prior1YearDuration | 869000000 | JPY |
| Other noi | CurrentYearDuration | 741000000 | JPY |
| Non operating income | Prior1YearDuration | 3847000000 | JPY |
| Non operating income | CurrentYearDuration | 4372000000 | JPY |
| Interest expenses noe | Prior1YearDuration | 51000000 | JPY |
| Interest expenses noe | CurrentYearDuration | 42000000 | JPY |
| Rent expenses on real estates noe | Prior1YearDuration | 252000000 | JPY |
| Rent expenses on real estates noe | CurrentYearDuration | 316000000 | JPY |
| Other noe | Prior1YearDuration | 241000000 | JPY |
| Other noe | CurrentYearDuration | 242000000 | JPY |
| Non operating expenses | Prior1YearDuration | 545000000 | JPY |
| Non operating expenses | CurrentYearDuration | 601000000 | JPY |
| Ordinary income | Prior1YearDuration | 23418000000 | JPY |
| Ordinary income | CurrentYearDuration | 36376000000 | JPY |
| Gain on sales of noncurrent assets ei | Prior1YearDuration | 825000000 | JPY |
| Gain on sales of noncurrent assets ei | CurrentYearDuration | 78000000 | JPY |
| Gain on sales of investment securities ei | Prior1YearDuration | 7333000000 | JPY |
| Gain on sales of investment securities ei | CurrentYearDuration | 58000000 | JPY |
| Gain on transfer of business ei | Prior1YearDuration | － | JPY |
| Gain on transfer of business ei | CurrentYearDuration | 25000000 | JPY |
| Compensation income ei | Prior1YearDuration | － | JPY |
| Compensation income ei | CurrentYearDuration | 30000000 | JPY |
| Other ei | Prior1YearDuration | 33000000 | JPY |
| Other ei | CurrentYearDuration | 16000000 | JPY |
| Extraordinary income | Prior1YearDuration | 8192000000 | JPY |
| Extraordinary income | CurrentYearDuration | 209000000 | JPY |
| Loss on sales and retirement of noncurrent assets el | Prior1YearDuration | 146000000 | JPY |
| Loss on sales and retirement of noncurrent assets el | CurrentYearDuration | 219000000 | JPY |
| Impairment loss el | Prior1YearDuration | 1848000000 | JPY |
| Impairment loss el | CurrentYearDuration | 1019000000 | JPY |
| Special retirement expenses el | Prior1YearDuration | 4814000000 | JPY |
| Special retirement expenses el | CurrentYearDuration | 15000000 | JPY |
| Loss on antimonopoly law el | Prior1YearDuration | 2000000000 | JPY |
| Loss on antimonopoly law el | CurrentYearDuration | 4447000000 | JPY |
| Other el | Prior1YearDuration | 314000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |